Loading clinical trials...
Loading clinical trials...
A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Conditions
Interventions
rivogenlecleucel
Rimiducid
Start Date
May 1, 2016
Primary Completion Date
December 1, 2018
Completion Date
December 1, 2018
Last Updated
October 5, 2020
NCT07388563
NCT00106925
NCT06311227
NCT06285890
NCT06852222
NCT06220162
Lead Sponsor
Bellicum Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions